UNSPSC 51145001: Linopirdine

This classification denotes a cation channel blocker with the molecular formula C26H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) I5TB3NZ94T, chemically known as 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2h-indol-2-one but more generally known as linopirdine, which bears US NIH Compound Identifier 3932. European Medicines Agency schedules Linopirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08522MIG.

UNSPSC 51145001 Linopirdine is a Commodity code that nominally covers a single pharmaceutical compound, but recent state and local procurement activity tagged under this code actually solicits naloxone, generic multi-source pharmaceuticals, and over-the-counter products through diverse supply and distribution arrangements. State and local buyers under this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The work involves competitive procurement of pharmaceutical products for community health initiatives, emergency response systems, and routine health facility operations, with vendors expected to meet FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act requirements, and specific insurance coverage thresholds.

Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP cooperative purchasing vehicle extending coverage to Oregon and other allied states. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers with awards effective July 1, 2026. The MMCAP procurement weights pricing competitiveness at 75 percent and requires vendors to maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000.